Key Highlights
- Continued dominance of global pharmaceutical sponsors
- Oncology remains the leading therapeutic area
- Broad phase distribution with a strong concentration in Phase II–III studies
- Increasing activity in rare disease and neuromuscular programs
- Growing number of innovative modalities including ADCs, CAR-T therapies, and bispecific antibodies
The June 2026 approval data continues to demonstrate Korea’s importance within global clinical development strategies. Multinational pharmaceutical companies and global biotechnology sponsors accounted for the large majority of approvals, reinforcing Korea’s position as a preferred execution country for multinational clinical trials and registration-focused development programs.
From a therapeutic area perspective, oncology remained the dominant segment. Multiple studies were approved across advanced solid tumors, prostate cancer, non-small cell lung cancer, multiple myeloma, follicular lymphoma, gastrointestinal stromal tumor, urothelial cancer, and gynecologic cancers including ovarian and endometrial cancer. This reflects the continued confidence of sponsors in Korea’s oncology infrastructure, experienced investigators, and ability to support complex patient recruitment requirements, even as growing competition for patient access continues to raise the importance of strategic site selection.
Phase distribution was broad, spanning Phase I through Phase IV, with Phase II and Phase III studies together accounting for the largest share of approvals. At the same time, a notable number of first-in-human and early Phase I studies were approved, indicating that Korea continues to be considered not only for late-stage confirmatory work but also for early clinical validation of new candidates.
Beyond oncology, approvals were observed across a wide range of therapeutic areas, including metabolic disease, autoimmune and rheumatologic conditions such as lupus, inflammatory bowel disease, and myositis, rare and neuromuscular disorders including Angelman syndrome and myotonic dystrophy, neurodegenerative disease, and ophthalmology. This growing diversity suggests that Korea is expanding well beyond its traditional strengths and is becoming increasingly important across a broader range of clinical development programs.
Another notable trend is the continued presence of innovative modalities and next-generation therapeutics, including antibody-drug conjugates, CAR-T and autologous cell therapies, bispecific antibodies, AAV-based gene therapy, and radioligand therapy. This indicates that Korea is not only serving as an execution market for late-stage development but is also becoming an important location for early clinical validation of emerging technologies.